HRP20150196T1 - Farmaceutske formulacije s ligandima receptora dopamina - Google Patents

Farmaceutske formulacije s ligandima receptora dopamina Download PDF

Info

Publication number
HRP20150196T1
HRP20150196T1 HRP20150196TT HRP20150196T HRP20150196T1 HR P20150196 T1 HRP20150196 T1 HR P20150196T1 HR P20150196T T HRP20150196T T HR P20150196TT HR P20150196 T HRP20150196 T HR P20150196T HR P20150196 T1 HRP20150196 T1 HR P20150196T1
Authority
HR
Croatia
Prior art keywords
mean
piperazin
dichlorophenyl
trans
ethyl
Prior art date
Application number
HRP20150196TT
Other languages
English (en)
Inventor
Ranajoy Sarkar
Mahendra G. Dedhiya
Anil Chhettry
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150196(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20150196T1 publication Critical patent/HRP20150196T1/hr

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N25/00—Circuitry of solid-state image sensors [SSIS]; Control thereof
    • H04N25/70—SSIS architectures; Circuits associated therewith
    • H04N25/71—Charge-coupled device [CCD] sensors; Charge-transfer registers specially adapted for CCD sensors
    • H04N25/75—Circuitry for providing, modifying or processing image signals from the pixel array
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N25/00—Circuitry of solid-state image sensors [SSIS]; Control thereof
    • H04N25/70—SSIS architectures; Circuits associated therewith
    • H04N25/76—Addressed sensors, e.g. MOS or CMOS sensors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Multimedia (AREA)
  • Hospice & Palliative Care (AREA)
  • Signal Processing (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Farmaceutska formulacija, u čvrstom obliku, za oralno doziranje, koja obuhvaća trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil ureu ili farmaceutski primjenjivu sol te tvari, pufersko sredstvo ili pomoćnu tvar, odabranu iz prethodno želatiniranog škroba i suhog kalcij-hidrogenfosfata, naznačena time da formulacija sadrži manje od 1% G/G trans-4-[2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl]-cyclohexylamina ili jednu farmaceutski primjenjivu sol tog spoja.
2. Formulacija, prema zahtjevu 1, koja obuhvaća od oko 0,5 do oko 15 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, naznačena time da formulacija daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 26,3 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 10 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
3. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća od oko 0,5 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 0,9 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 10 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
4. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 1 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 1,8 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 20 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
5. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 1,5 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 2,7 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 30 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
6. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 2 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 3,5 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego oko 40 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
7. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 2,5 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 4,4 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 50 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
8. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 3 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 5,3 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 60 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
9. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 6 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili jednu farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 10,5 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 120 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
10. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 9 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 15,8 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 180 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
11. Formulacija prema zahtjevu 2, naznačena time da formulacija obuhvaća oko 12,5 mg trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil uree ili jednu farmaceutski primjenjivu sol tog spoja, i daje jedan in vivo-plazmaprofil, obuhvaćajući: (i) jedan srednji Cmax. od manje nego 21,9 ng/ml, (ii) jednu srednju AUC 0-∞ od više nego 250 ng/h/ml i (iii) jednu srednju Tmax od oko 3 ili više sati.
12. Formulacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da formulacija obuhvaća trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil urea-hidroklorid.
13. Formulacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da obuhvaća: (a) Između oko 0,5% i oko 15 % trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil urea-hidroklorida, (b) Između oko 0,1% i oko 20% natrij karbonata, (c) Između 0% i oko 10% talka, (d) Između 0% i oko 5% koloidalnog silicij dioksida, (e) Između 0% i oko 15% natrij-glikolata škroba, (f) Između oko 5% i oko 95% mikrokristalne celuloze i (g) Između oko 0,1% i oko 3% magnezij-stearata.
14. Formulacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da formulacija obuhvaća trans-1{4-[2-[4-(2,3-diklorfenil)-piperazin-1-il]-etil]-cikloheksil}-3,3-dimetil ureu ili farmaceutski primjenjivu sol tog spoja s količinom od više od oko 80%, koja bude oslobođena unutar prvih 60 minuta, nakon aplikacije formulacije, kod potrebitih pacijenata.
15. Formulacija prema zahtjevu 1 ili zahtjevu 2 naznačena time da se primjenjuje u postupku liječenja šizofrenije, biplolarnog poremećaja ili akutne manije.
HRP20150196TT 2008-07-16 2015-02-19 Farmaceutske formulacije s ligandima receptora dopamina HRP20150196T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8105208P 2008-07-16 2008-07-16
EP09798745.7A EP2317852B1 (en) 2008-07-16 2009-07-16 Pharmaceutical formulations containing dopamine receptor ligands
PCT/US2009/050835 WO2010009309A1 (en) 2008-07-16 2009-07-16 Pharmaceutical formulations containing dopamine receptor ligands

Publications (1)

Publication Number Publication Date
HRP20150196T1 true HRP20150196T1 (hr) 2015-06-05

Family

ID=41530841

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150196TT HRP20150196T1 (hr) 2008-07-16 2015-02-19 Farmaceutske formulacije s ligandima receptora dopamina

Country Status (33)

Country Link
US (6) US9056845B2 (hr)
EP (1) EP2317852B1 (hr)
JP (1) JP5774988B2 (hr)
KR (1) KR101612146B1 (hr)
CN (2) CN102118970A (hr)
AP (1) AP2975A (hr)
AU (1) AU2009270823B2 (hr)
BR (1) BRPI0916241A2 (hr)
CA (1) CA2730287C (hr)
CL (1) CL2011000091A1 (hr)
CO (1) CO6351689A2 (hr)
CY (1) CY1115994T1 (hr)
DK (1) DK2317852T3 (hr)
EA (1) EA025636B1 (hr)
EC (1) ECSP11010834A (hr)
ES (1) ES2532636T3 (hr)
GE (1) GEP20146052B (hr)
HR (1) HRP20150196T1 (hr)
IL (1) IL210615A (hr)
MA (1) MA32568B1 (hr)
MX (1) MX2011000622A (hr)
MY (1) MY156288A (hr)
NI (1) NI201100016A (hr)
NZ (1) NZ590852A (hr)
PL (1) PL2317852T3 (hr)
PT (1) PT2317852E (hr)
RS (1) RS53866B1 (hr)
SG (1) SG192507A1 (hr)
SI (1) SI2317852T1 (hr)
SM (1) SMT201500063B (hr)
UA (1) UA104869C2 (hr)
WO (1) WO2010009309A1 (hr)
ZA (1) ZA201101134B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR101563383B1 (ko) * 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8717044B2 (en) * 2010-04-23 2014-05-06 Apple Inc. Charging systems with direct charging port support and extended capabilities
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
EP3231418A1 (en) * 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107970217A (zh) * 2016-10-25 2018-05-01 浙江京新药业股份有限公司 卡利拉嗪口腔崩解片及其制备方法
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN109589315A (zh) * 2017-10-01 2019-04-09 北京万全德众医药生物技术有限公司 卡利拉嗪-亲水性材料共混物固体制剂的制备方法
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HUP2200312A1 (hu) * 2022-08-05 2024-02-28 Richter Gedeon Nyrt Kariprazin tartalmú szájban diszpergálódó tabletta

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666911A (en) 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4880797A (en) 1986-03-20 1989-11-14 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives and antibacterial agents
JPH01199977A (ja) 1987-11-16 1989-08-11 Mochida Pharmaceut Co Ltd セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物
GB8802622D0 (en) 1988-02-05 1988-03-02 Glaxo Group Ltd Chemical compound
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
JPH04275280A (ja) 1991-03-04 1992-09-30 Nippon Chem Ind Co Ltd ４ｈ−２，３−ジヒドロ−２−イミノ−１，３−ベンゾチアジン−４−オン類の製造方法
JPH0532586A (ja) 1991-07-26 1993-02-09 Mitsubishi Petrochem Co Ltd ２，６−ナフタレンジカルボン酸の製造方法
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
JPH05310745A (ja) 1992-05-13 1993-11-22 Takeda Chem Ind Ltd ジエラジラクトンおよび抗炎症剤
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US20010009912A1 (en) 1995-02-10 2001-07-26 Christos Tsaklakidis New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds
DE69617700T2 (de) * 1995-08-18 2002-07-18 Purdue Research Foundation West Lafayette Neue kondensierten isochinoline als dopamin-rezeptor-liganden
AU6859096A (en) 1995-09-22 1997-04-09 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
NZ507204A (en) 1998-03-31 2003-12-19 Acadia Pharm Inc Substituted piperidine and piperazine derivatives having activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HUP0102609A3 (en) 1998-06-30 2002-12-28 Zeria Pharm Co Ltd N-phenyl-n'-phenylpropylpiperazine derivatives and process for the preparation thereof, and pharmaceutical compositions containing them
CZ300551B6 (cs) * 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US20070009931A1 (en) * 2000-08-04 2007-01-11 Kirsch Wolff M Negative correlation between IRP-2 and Transferrin receptor expression as a diagnostic of Alzheimer's disease
MXPA03007716A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
WO2002100350A2 (en) * 2001-06-13 2002-12-19 The Regents Of University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
CN101005829A (zh) 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
KR100641825B1 (ko) 2003-11-05 2006-11-02 주식회사 코오롱 4-바이페닐아세트산의 제조 방법
US20070099931A1 (en) 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
DE102004047517A1 (de) 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
UY29161A1 (es) 2004-10-15 2006-04-28 Bayer Pharmaceuticals Corp Nuevos heterociclos
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
KR20150023937A (ko) 2007-05-11 2015-03-05 리히터 게데온 닐트. 카르바모일-사이클로헥산 유도체의 신규한 용매화물 및 결정 형태
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
WO2009015667A1 (en) 2007-08-01 2009-02-05 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
WO2009020897A1 (en) 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR101563383B1 (ko) 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HU229858B1 (en) 2008-12-17 2014-10-28 Richter Gedeon Nyrt Process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester hcl
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010126527A1 (en) 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2011060363A2 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
CA2872689C (en) 2012-05-07 2021-03-30 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
US10028948B2 (en) 2013-12-13 2018-07-24 Pierre Fabre Medicament Chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder
CN105218484B (zh) 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN105330616B (zh) 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Also Published As

Publication number Publication date
CO6351689A2 (es) 2011-12-20
EP2317852A1 (en) 2011-05-11
EA201170198A1 (ru) 2011-08-30
ZA201101134B (en) 2011-10-26
CL2011000091A1 (es) 2011-07-22
ECSP11010834A (es) 2011-04-29
JP2011528374A (ja) 2011-11-17
AU2009270823B2 (en) 2014-07-17
MX2011000622A (es) 2011-04-07
AU2009270823A1 (en) 2010-01-21
IL210615A (en) 2015-03-31
JP5774988B2 (ja) 2015-09-09
GEP20146052B (en) 2014-03-10
IL210615A0 (en) 2011-03-31
USRE49110E1 (en) 2022-06-21
CA2730287A1 (en) 2010-01-21
MA32568B1 (fr) 2011-08-01
US9056845B2 (en) 2015-06-16
CA2730287C (en) 2017-02-07
DK2317852T3 (en) 2015-03-23
AP2011005549A0 (en) 2011-02-28
CY1115994T1 (el) 2017-01-25
WO2010009309A1 (en) 2010-01-21
RS53866B1 (en) 2015-08-31
EP2317852A4 (en) 2011-10-05
SMT201500063B (it) 2015-05-05
NZ590852A (en) 2013-03-28
KR101612146B1 (ko) 2016-04-12
AP2975A (en) 2014-09-30
US20100016334A1 (en) 2010-01-21
EP2317852B1 (en) 2014-12-24
US9056846B2 (en) 2015-06-16
MY156288A (en) 2016-01-29
NI201100016A (es) 2011-08-03
UA104869C2 (uk) 2014-03-25
USRE47333E1 (en) 2019-04-02
EA025636B1 (ru) 2017-01-30
CN102118970A (zh) 2011-07-06
BRPI0916241A2 (pt) 2017-06-27
SG192507A1 (en) 2013-08-30
US20130040966A1 (en) 2013-02-14
PL2317852T3 (pl) 2015-05-29
USRE47350E1 (en) 2019-04-16
CN104997743A (zh) 2015-10-28
SI2317852T1 (sl) 2015-04-30
KR20110033852A (ko) 2011-03-31
USRE49302E1 (en) 2022-11-15
ES2532636T3 (es) 2015-03-30
PT2317852E (pt) 2015-03-24

Similar Documents

Publication Publication Date Title
HRP20150196T1 (hr) Farmaceutske formulacije s ligandima receptora dopamina
HRP20191587T1 (hr) Formulacije s trenutnim oslobađanjem za oralnu primjenu supstituiranih kinazolinona
JP6084161B2 (ja) ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤
JP2018021007A5 (hr)
JP2014532638A5 (hr)
NO20083104L (no) Fast preparat
JP2007509155A5 (hr)
HRP20192026T4 (hr) Formulacija tableta od neratinib maleata
ES2311442T1 (es) Dosis en forma oral.
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
TNSN08018A1 (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
ES2938261T3 (es) Comprimido de ribociclib
PE20040416A1 (es) Formulacion de alta dosis de ibandronato
JP2017537954A5 (hr)
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
HRP20110113T1 (hr) Kapecitabin tablete za djecu
CN106029637A (zh) 新的组合物
CO5700753A2 (es) Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad
ES2375265T3 (es) Composiciones farmacéuticas de pramipexol.
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
JP2007197410A (ja) フィルムコーティング錠
PE20100471A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
ES2404811T3 (es) Formulaciones farmacéuticas de olmesartán
HRP20130225T1 (hr) Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol
RS51211B (sr) Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja